Last reviewed · How we verify

Pentoxifylline Oral Tablet

Mansoura University · FDA-approved active Small molecule Quality 2/100

Pentoxifylline Oral Tablet, developed by Mansoura University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its extended patent protection. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic namePentoxifylline Oral Tablet
Also known asIntravenous doxorubicin, Intravenous cyclophosphamide, Intravenous taxane, TRENtal, Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
SponsorMansoura University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: